TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced alongside the Centre for Addiction and Mental Health (CAMH) in Toronto, one of the world’s leading mental-health research hospitals, that they have been named recipients of the prestigious Ontario Research Fun ...

Core Insights - NEXGEL, Inc. has announced a strategic investment in its spin-off NexGelRx from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC, which will enhance its drug delivery application assets [1] - Mr. Gruntfest has been appointed as a board observer and advisor for NexGelRx, bringing over 20 years of experience in reimbursement strategy and healthcare commercialization [2] - The CEO of NexGelRx, Richard Myers, expressed confidence that Mr. Gruntfest's insights will provide a new perspective and strengthen the company's stakeholder base [3] Company Overview - NEXGEL is a provider of healthcare, beauty, and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogel products for various applications [3] - The company has been developing and manufacturing electron-beam, cross-linked hydrogels for over two decades and has established brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] - NEXGEL maintains strategic contract manufacturing relationships with leading consumer healthcare companies, positioning itself strongly in the market [3]

Core Viewpoint - The drugmaker has revised its revenue guidance for 2025, now expecting $62 billion in revenue for the year [1] Summary by Category - **Revenue Guidance** - The company anticipates a revenue of $62 billion for the year 2025 [1]

Market Analysis by covering: Pfizer Inc. Read 's Market Analysis on Investing.com ...

Pfizer expects revenue and earnings to fall in 2026. ...

Core Insights - The State Street Health Care Select Sector SPDR ETF (XLV) is a passively managed ETF launched on December 16, 1998, providing broad exposure to the Healthcare - Broad segment of the equity market [1] - XLV is the largest ETF in its category, with assets exceeding $40.99 billion, and aims to match the performance of the Health Care Select Sector Index [3] Fund Details - The ETF has an annual operating expense ratio of 0.08%, making it the least expensive option in the healthcare ETF space, with a 12-month trailing dividend yield of 1.56% [5] - The fund is fully allocated to the healthcare sector, with top holdings including Eli Lilly + Co (12.97%), Johnson + Johnson, and Abbvie Inc, which together account for approximately 57.14% of total assets [6][7] Performance Metrics - As of December 16, 2025, XLV has returned approximately 14.79% year-to-date and 12.45% over the past year, with a trading range between $128.77 and $158.77 in the last 52 weeks [8] - The ETF has a beta of 0.61 and a standard deviation of 13.38% over the trailing three-year period, indicating a medium risk profile [8] Alternatives - Other healthcare ETFs include iShares Global Healthcare ETF (IXJ) with $4.52 billion in assets and Vanguard Health Care ETF (VHT) with $17.53 billion, each with different expense ratios [11]

Pfizer forecast little growth in sales for next year as the drugmaker looks to refresh its pipeline of hit drugs with a series of pricey acquisitions https://t.co/iqTRppXFph ...

Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a share. ...

Group 1 - Health care stocks have outperformed the S&P 500 over the past three months, with an average gain of 11.55%, but Pfizer's shares have declined by 5% since the start of October [3][8] - Other major pharmaceutical companies like Johnson & Johnson, Regeneron Pharmaceuticals, and Eli Lilly have seen significant gains of nearly 14%, 24%, and 25% respectively during the same period [4] - Pfizer's recent acquisition of obesity biotech Metsera for $10 billion has only resulted in a modest 0.23% gain in its stock since the announcement [4] Group 2 - Pfizer is aiming to expand its presence in the weight loss drug market to recover revenue lost from declining demand for mRNA-based COVID-19 vaccines [5][8] - The company has entered into a $2.1 billion licensing agreement with China's YaoPharma to develop a GLP-1 weight loss pill, which is in early-stage development [5][8] - The agreement includes an upfront payment of $150 million to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, and potential milestone payments of up to $1.94 billion based on the drug's approval progress [6][7]

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies CHATHAM, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced licensing exclusive worldwide rights to TNX-4900 (formerly known as PW507), a highly selective small ...